We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Former FDA Official Says Agency Was Right to Approve Aduhelm
Former FDA Official Says Agency Was Right to Approve Aduhelm
GOTHENBURG, SWEDEN — The FDA correctly approved Biogen’s Aduhelm (aducanumab) in 2021 because the drug met the criteria for disease modification the agency had laid down for Alzheimer’s disease (AD) drug sponsors years before, according to a former FDA employee.